Darshan Tolat, MD
Nephrology · Conroe, TXNPI 1063418515
Payments from drug & device makers
Across 56 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$356
- Mallinckrodt Hospital Products Inc.$263
- Otsuka America Pharmaceutical, Inc.$171
- Bayer$114
- Novartis$57
- Akebia Therapeutics Inc$37
- plus $161 from 7 others
What the payments were for
- Food & beverage$1,02689%
- Education$13111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $356 |
| Mallinckrodt Hospital Products Inc. | 13 | $263 |
| Otsuka America Pharmaceutical, Inc. | 8 | $171 |
| Bayer | 5 | $114 |
| Novartis | 3 | $57 |
| Akebia Therapeutics Inc | 2 | $37 |
| Calliditas Therapeutics US Inc. | 2 | $35 |
| Novo Nordisk | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Renalytix AI, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Abbott | 1 | $16 |
| Sanofi | 1 | $15 |
How this compares
$1,158 in reported general payments places this provider in the 40th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 16 | $38,625 |
| Sevelamer Carbonate | 23 | $5,507 |
| Potassium Citrate ErPotassium Citrate | 37 | $2,141 |
| Furosemide | 327 | $2,124 |
| Amlodipine Besylate | 258 | $1,448 |
| Metoprolol Succinate | 100 | $1,210 |
| Alprazolam | 38 | $1,178 |
| Calcium Acetate | 13 | $1,146 |
| Potassium Chloride | 50 | $1,056 |
| Tamsulosin Hcl | 73 | $1,035 |
| Bumetanide | 19 | $835 |
| Metolazone | 18 | $685 |
| Rosuvastatin Calcium | 28 | $617 |
| Losartan Potassium | 45 | $613 |
| Doxazosin Mesylate | 40 | $606 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Conroe
- Pablo PergolaSan Antonio$14.2M
- German HernandezEl Paso$9.7M
- Sreedhar MandayamHouston$7M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Marializa BernardoHouston$4.2M
- Judith BettsAustin$3.7M
- Wesley CalhounSan Antonio$3.5M
- Adam FromeThe Woodlands$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.